157 related articles for article (PubMed ID: 9519149)
1. Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue.
DeFelippis MR; Bakaysa DL; Bell MA; Heady MA; Li S; Pye S; Youngman KM; Radziuk J; Frank BH
J Pharm Sci; 1998 Feb; 87(2):170-6. PubMed ID: 9519149
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
Roach P; Woodworth JR
Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
[TBL] [Abstract][Full Text] [Related]
3. Preparation of a microcrystalline suspension formulation of Lys(B28)Pro(B29)-human insulin with ultralente properties.
Richards JP; Stickelmeyer MP; Frank BH; Pye S; Barbeau M; Radziuk J; Smith GD; DeFelippis MR
J Pharm Sci; 1999 Sep; 88(9):861-7. PubMed ID: 10479347
[TBL] [Abstract][Full Text] [Related]
4. Structural studies of a crystalline insulin analog complex with protamine by atomic force microscopy.
Yip CM; Brader ML; Frank BH; DeFelippis MR; Ward MD
Biophys J; 2000 Jan; 78(1):466-73. PubMed ID: 10620310
[TBL] [Abstract][Full Text] [Related]
5. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
[TBL] [Abstract][Full Text] [Related]
6. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin.
Howey DC; Bowsher RR; Brunelle RL; Woodworth JR
Diabetes; 1994 Mar; 43(3):396-402. PubMed ID: 8314011
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of insulin NPH formulations.
Norrman M; Hubálek F; Schluckebier G
Eur J Pharm Sci; 2007 Apr; 30(5):414-23. PubMed ID: 17339105
[TBL] [Abstract][Full Text] [Related]
8. Reversible adsorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: an electrostatic interaction.
Dodd SW; Havel HA; Kovach PM; Lakshminarayan C; Redmon MP; Sargeant CM; Sullivan GR; Beals JM
Pharm Res; 1995 Jan; 12(1):60-8. PubMed ID: 7724489
[TBL] [Abstract][Full Text] [Related]
9. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.
Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ
Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909
[TBL] [Abstract][Full Text] [Related]
10. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
[TBL] [Abstract][Full Text] [Related]
11. A novel protein cross-linking reaction in stressed Neutral Protamine Hagedorn formulations of insulin.
Beavis RC; Kneirman MD; Sharknas D; Heady MA; Frank BH; DeFelippis MR
J Pharm Sci; 1999 Mar; 88(3):331-6. PubMed ID: 10052992
[TBL] [Abstract][Full Text] [Related]
12. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.
Heise T; Weyer C; Serwas A; Heinrichs S; Osinga J; Roach P; Woodworth J; Gudat U; Heinemann L
Diabetes Care; 1998 May; 21(5):800-3. PubMed ID: 9589244
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation.
Mudaliar SR; Mohideen P; Baxi SC; Joyce M; Armstrong DA; Strange P; Henry RR
Clin Ther; 2001 Mar; 23(3):404-12. PubMed ID: 11318075
[TBL] [Abstract][Full Text] [Related]
14. The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery.
Zhang Y; Zhu J; Tang Y; Chen X; Yang Y
Drug Dev Ind Pharm; 2009 Sep; 35(9):1059-65. PubMed ID: 19640250
[TBL] [Abstract][Full Text] [Related]
15. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
16. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
Heinemann L; Heise T; Klepper A; Ampudia J; Bender R; Starke AA
Diabete Metab; 1995 Dec; 21(6):415-9. PubMed ID: 8593922
[TBL] [Abstract][Full Text] [Related]
17. Systemic delivery of insulin via the nasal route using a new microemulsion system: In vitro and in vivo studies.
Sintov AC; Levy HV; Botner S
J Control Release; 2010 Dec; 148(2):168-76. PubMed ID: 20709120
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and variability of biphasic insulin mixtures.
Søeborg T; Rasmussen CH; Mosekilde E; Colding-Jørgensen M
Eur J Pharm Sci; 2012 Jul; 46(4):198-208. PubMed ID: 21703346
[TBL] [Abstract][Full Text] [Related]
19. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
20. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
